Stereotaxis, Inc. (STXS) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Stereotaxis, Inc. (STXS) stock forecast summary
On Oct. 16, 2026, STXS is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.
Stereotaxis, Inc. is a small-cap company with a market capitalization of $101M. It ranks number 14 by market capitalization among the 30 Electromedical & Electrotherapeutic Apparatus issuers in our coverage with a current forecast.
For STXS, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 40.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 27.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, STXS included.
Follow STXS freeSTXS price chart and AI forecast
How STXS ranks among 5172 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Stereotaxis, Inc. (STXS) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Electromedical & Electrotherapeutic Apparatus peers listed below that report each metric.
Valuation & Market
| Metric | STXS | Rank |
|---|---|---|
| Market Cap | $101M | 14/30 |
| EPS | $-0.25 | – |
| Revenue/Share | $0.30 | – |
| FCF/Share | $-0.15 | – |
Profitability & Margins
| Metric | STXS | Rank |
|---|---|---|
| Gross Margin | 55.3% | 15/27 |
| Operating Margin | -75.3% | 21/28 |
| EBT Margin | -75.3% | 20/28 |
Financial Health
| Metric | STXS | Rank |
|---|---|---|
| Current Ratio | 1.42x | 23/30 |
| Quick Ratio | 0.95x | 23/29 |
| Interest Coverage | -45.7x | 20/30 |
| Working Capital | $11M | 19/29 |
Cash Flow
| Metric | STXS | Rank |
|---|---|---|
| Operating Cash Flow | -$15M | 24/30 |
| Free Cash Flow | -$16M | 9/14 |
| Capital Spending | -$210K | 3/14 |
| FCF/Sales | -51.6% | 10/14 |
| CapEx/Sales | 0.7% | 10/14 |
Operational Efficiency
| Metric | STXS | Rank |
|---|---|---|
| Receivables Turnover | 4.0x | 16/20 |
| Inventory Turnover | 1.1x | 23/27 |
| Fixed Assets Turnover | 10.4x | 12/20 |
| Days Sales Outstanding | 92 days | 5/20 |
| Days Inventory | 342 days | 5/27 |
| Payables Period | 188 days | 6/24 |
| Cash Conversion Cycle | 246 days | 4/19 |
Income Statement
| Metric | STXS | Rank |
|---|---|---|
| Total Revenue | $30M | 13/19 |
| Operating Income | -$23M | 24/30 |
| R&D Expense | $10M | 14/28 |
| SG&A Expense | $46M | 12/26 |
| Cost of Goods Sold | $13M | 15/27 |
Dividend & Shareholder Information
| Metric | STXS | Rank |
|---|---|---|
| Shares Outstanding | 100M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $38M | |
| Cash & Short-term Investments | $10M | 98.3% of assets |
| Accounts Receivable | $8M | 70.8% of assets |
| Inventory | $13M | |
| Total Liabilities | $31M | |
| Short-term Debt | $20M |
STXS quarterly financials and insider trading
Stereotaxis, Inc. (STXS) industry peers
Companies classified under the same SEC industry code as Stereotaxis, Inc. (Electromedical & Electrotherapeutic Apparatus): 32 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| STXS Stereotaxis, Inc. | ▶ | $101M |
| MDT Medtronic Plc | ▼ | $121.20B |
| ITGR Integer Holdings Corp | ▼ | $4.31B |
| LIVN Livanova Plc | ▼ | $4.27B |
| TMDX Transmedics Group, Inc. | ▲ | $2.45B |
| BLFS Biolife Solutions Inc | ▶ | $1.89B |
| AXGN Axogen, Inc. | ▲ | $1.86B |
| CNMD Conmed Corp | ▼ | $1.40B |
| CBLL Ceribell, Inc. | ▲ | $961M |
| INMD Inmode Ltd. | ▼ | $814M |
| CV Capsovision, Inc | ▶ | $327M |
| ELMD Electromed, Inc. | ▼ | $229M |
| FOCL Edap Tms Sa | ▲ | $153M |
| VANI Vivani Medical, Inc. | ▶ | $104M |
| NRXS Neuraxis, Inc | ▲ | $97M |
| HYPR Hyperfine, Inc. | ▲ | $77M |
| OM Outset Medical, Inc. | ▲ | $77M |
| ECOR Electrocore, Inc. | ▲ | $71M |
| POSC Positron Corp | ▲ | $53M |
| VASO Vaso Corp | ▲ | $51M |
| POCI Precision Optics Corporation, Inc. | ▲ | $48M |
| QTI Qt Imaging Holdings, Inc. | ▶ | $35M |
| ITOC Itonic Holdings Ltd | ▼ | $28M |
| GTHP Guided Therapeutics Inc | ▲ | $18M |
| IRIX Iridex Corp | ▲ | $14M |
| NDRA Endra Life Sciences Inc. | ▶ | $7M |
| ADMT Adm Tronics Unlimited, Inc. | ▶ | $3M |
| NXL Nexalin Technology, Inc. | ▼ | $2M |
| NUWE Nuwellis, Inc. | ▼ | $2M |
| ESMC Escalon Medical Corp | ▲ | $1M |
| HCIL Hongchang International Co., Ltd | ▼ | N/A |
| YBGJ Yubo International Biotech Ltd | ▶ | N/A |
Where STXS sits on the market map
Stereotaxis, Inc. (STXS) stock news
Loading...
Stereotaxis, Inc. (STXS) stock forecast FAQ
What is the Stereotaxis, Inc. (STXS) stock forecast?
On Oct. 16, 2026, STXS is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.
How accurate are Stereotaxis, Inc. stock predictions?
For STXS, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 40.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 27.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Stereotaxis, Inc. forecasts updated?
Stereotaxis, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Stereotaxis, Inc.'s industry peers?
32 issuers in our coverage, STXS included, share the SEC industry code Electromedical & Electrotherapeutic Apparatus. The largest are: Medtronic Plc (MDT), Integer Holdings Corp (ITGR), Livanova Plc (LIVN), Transmedics Group, Inc. (TMDX), Biolife Solutions Inc (BLFS), Axogen, Inc. (AXGN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.